ATP-III reports have identified low-density lipoprotein cholesterol (LDL-C) as the primary target of cholesterol-lowering therapy. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III ) provides evidence-based recommendations on the management of high blood cholesterol and related disorders. This study confirms that pantethine lowers cardiovascular risk markers in low to moderate CVD risk participants eligible for statins according to NCEP guidelines. After 16 weeks, the participants on placebo did not show significant improvement in any CVD risk end points. Coenzyme Q 10 significantly increased from baseline to week 4 and remained elevated until week 16, in both the pantethine and placebo groups. The homocysteine levels for both groups did not change significantly from baseline to week 16. This decrease was significant between groups at weeks 8 ( P=0.027) and 16 ( P=0.010). An 11% decrease in LDL-C from baseline was seen in participants on pantethine, at weeks 4, 8, 12, and 16, while participants on placebo showed a 3% increase at week 16. Compared with placebo, the participants on pantethine showed a significant decrease in total cholesterol at 16 weeks ( P=0.040) and LDL-C at 8 and 16 weeks ( P=0.020 and P=0.006, respectively), and decreasing trends in non-high-density lipoprotein cholesterol at week 8 and week 12 ( P=0.102 and P=0.145, respectively) that reached significance by week 16 ( P=0.042). A total of 32 subjects were randomized to pantethine (600 mg/day from weeks 1 to 8 and 900 mg/day from weeks 9 to16) or placebo. The efficacy of pantethine treatment on cardiovascular risk markers was investigated in a randomized, triple-blinded, placebo-controlled study, in a low to moderate cardiovascular disease (CVD) risk North American population eligible for statin therapy, using the National Cholesterol Education Program (NCEP) guidelines.
High serum concentration of low-density lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease.
0 kommentar(er)
